Connect with us


Lexaria Bioscience Corp. (OTCMKTS:LXRP) Can Carry Out an Investigative Clinical Study for Blood Pressure Reduction Using Cannabidiol; Ethics Board Says



Lexaria Bioscience Corp. (OTCMKTS:LXRP) is the company behind the proprietary drug delivery technology, DehydraTECH™. The technology licensed to multiple companies in the cannabis industry is used alongside cannabinoid beverages and different ingestible product formats. The technology’s primary role is to enhance the delivery of active pharmaceutical ingredients (APIs), which must be in low dosage.

The company says that through the use of cannabidiol formulated together with the patented technology; it will be carrying out an exploratory clinical study. The aim is to evaluate the reduction of blood pressure in volunteers with pre- or mild hypertension. This has received an endorsement from the Ethics board.

The Study is Likely to Be of Interest to Potential Future Pharmaceutical Partners

This is a new study, which will get many by surprise because Lexaria did not disclose it. It will enroll 24 volunteers, 12 males and 12 females, all aged 45-70 years. They will each receive a 300 mg dose of CBD with or without DehydraTECHTM formulation across two separate study visits. Both primary and secondary outcomes will be considered in picking out the key inflammatory indicators allied to cardiovascular disease.

The study should complement a previous one conducted in 2018, according to the CEO of Lexaria, Chris Bunka. He explained, “…Positive results in this study are expected to be of particular interest to the antihypertensive products sector that is valued at over $22 billion.”

Additionally, it will help the company strengthen its value proposition as it seeks out more partnership opportunities for its technology within the pharmaceutical industry.

Lexaria is a Global Leader In Improving The Speed And Efficiency Of Orally-Delivered Drugs

Since it started developing DehydraTECH™ technology in 2014, Lexaria has continued to thrive in its operations. This has been demonstrated through the success of its four wholly-owned subsidiary companies, all of which empowered with global exclusive licenses.

It is worth noting that more than 1billion people globally suffer from hypertension. Sadly, only 13% of them can put their condition under control. On the other hand, despite all the drug therapies, there are for hypertension, a majority of them are said to have a host of unwanted side effects such as reduced kidney function and other gastrointestinal issues.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.